Axsome delivered 65% year-over-year revenue growth in Q4 2025 driven by strong AUVELITY and SUNOSI sales, while substantially reducing its net loss compared to the prior year period.

Axsome Therapeutics delivered solid revenue growth in Q3 2025, primarily fueled by its leading CNS products AUVELITY and SUNOSI. Despite a reported net loss, the company saw sequential improvements in revenue and reduced losses year-over-year.

Axsome delivered solid revenue growth in Q2 2025, driven by continued momentum in AUVELITY and SUNOSI, and the launch of SYMBRAVO, while managing a reduced net loss year-over-year.

Axsome Therapeutics grew revenue significantly in Q1 2025, led by AUVELITY sales, but continued to report net losses amid ongoing R&D and commercialization efforts.

Axsome Therapeutics posted a 66% YoY increase in revenue, reaching $118.77 million in Q4 2024. Auvelity sales surged 89%, while Sunosi revenue grew 16%. Despite higher R&D and SG&A expenses, the company reduced its net loss compared to Q4 2023. Axsome remains focused on advancing its late-stage pipeline, with upcoming NDA submissions and the anticipated launch of Symbravo.

Axsome Therapeutics reported a total net product revenue of $104.8 million for Q3 2024, representing an 81% year-over-year growth. The company is also advancing its pipeline with multiple Phase 3 trial results expected soon and an NDA submission planned.

Axsome Therapeutics reported a strong second quarter in 2024, with total net product revenue reaching $87.2 million, representing an 87% year-over-year growth. The company is advancing its pipeline with NDA resubmission for AXS-07 and plans to submit NDA for AXS-14.

Axsome Therapeutics reported a total net product revenue of $75.0 million for Q1 2024, representing a 160% year-over-year growth. The company progressed its clinical trials, including positive Phase 3 results for AXS-12 in narcolepsy, and is preparing for NDA resubmissions for AXS-07 and AXS-14.

Axsome Therapeutics reported a transformational year in 2023, marked by successful commercial execution and substantial pipeline advancement. Total net product revenues for Q4 2023 were $71.5 million, a 193% increase year-over-year, driven by Auvelity and Sunosi sales. The company is advancing its pipeline with multiple Phase 3 trials and anticipates NDA submissions for AXS-07 and AXS-14 in the first half of 2024.

Axsome Therapeutics reported a total product revenue of $57.8 million for Q3 2023, a 244% increase year-over-year, driven by strong performances from Auvelity and Sunosi. The company is progressing its clinical programs, with multiple potential NDA submissions and pivotal trial readouts expected over the next 12 months.

Axsome Therapeutics reported a total product revenue of $46.7 million for Q2 2023, driven by Auvelity sales of $27.6 million and Sunosi revenue of $19.1 million. The company is expanding its Auvelity sales force and advancing its CNS pipeline with new indications for solriamfetol. They anticipate multiple clinical trial readouts and initiations in the near term.

Axsome Therapeutics reported a total revenue of $94.6 million for Q1 2023, driven by net product sales of $28.6 million and license revenue of $65.7 million. Auvelity net product sales were $15.7 million, and Sunosi net product sales were $12.9 million. The company's net loss for the quarter was $11.2 million, or $(0.26) per share.

Axsome Therapeutics reported Q4 2022 financial results, with total net sales of $24.4 million, including $5.2 million from Auvelity and $19.2 million from Sunosi. The company's net loss for the quarter was $61.2 million, or $(1.41) per share. The company had cash and cash equivalents of $200.8 million at the end of the year, and a pro forma cash balance in excess of $300 million after considering the Sunosi licensing agreement.

Axsome Therapeutics reported total revenues of $16.8 million for the third quarter of 2022, driven by U.S. net sales of Sunosi. The company's net loss was $44.8 million, or $(1.07) per share. The company believes that its current cash, along with the remaining committed capital from the $300 million term loan facility, is sufficient to fund anticipated operations into 2025.

Axsome Therapeutics reported a net loss of $39.6 million, or $(1.03) per share, for the first quarter ended March 31, 2022. The company's R&D expenses were $12.6 million, while G&A expenses were $25.7 million. Axsome had $84.7 million in cash as of March 31, 2022 and anticipates potential FDA action on the NDA in the second quarter of 2022.

Axsome Therapeutics reported a net loss of $34.0 million for the fourth quarter of 2021, compared to a net loss of $29.2 million for the same period in 2020. The company's R&D expenses were $13.8 million, and G&A expenses were $18.8 million. The company anticipates potential launches for AXS-05 and AXS-07.

Axsome Therapeutics reported financial results for the third quarter ended September 30, 2021. The company is advancing its late-stage CNS product candidates and preparing for potential commercial launches of AXS-05 and AXS-07, pending FDA approvals.

Axsome Therapeutics reported a net loss of $32.3 million, or $(0.86) per share, for the three months ended June 30, 2021. The FDA notified Axsome that they have identified deficiencies that preclude labeling discussions for AXS-05.

Axsome Therapeutics reported a net loss of $29.3 million, or $(0.78) per share, for the quarter ended March 31, 2021. The company's R&D expenses were $16.6 million, and G&A expenses were $11.2 million. Axsome had $164.7 million in cash as of March 31, 2021, and believes it is sufficient to fund operations into at least 2024.

Axsome Therapeutics reported a net loss of $29.2 million, or $(0.78) per share, for the quarter ended December 31, 2020. Research and development expenses were $17.4 million, while general and administrative expenses were $10.4 million. The company's cash position was $183.9 million at the end of the year.

Axsome Therapeutics reported a net loss of $22.9 million, or $(0.61) per share, for the third quarter ended September 30, 2020. The company's cash reserves totaled $202.4 million as of September 30, 2020, and the company believes that its cash along with committed capital will be sufficient to fund operations into at least 2024.

Axsome Therapeutics reported its Q2 2020 financial results, highlighting progress in its CNS pipeline with multiple FDA Breakthrough Therapy designations and advancements towards NDA submissions for AXS-05 and AXS-07. The company is on track with clinical trials and anticipates key milestones in the near term.

Axsome Therapeutics reported clinical successes in its late-stage pipeline, including positive efficacy data in depression, Alzheimer’s disease agitation, migraine, narcolepsy, and fibromyalgia. Two NDA submissions, for AXS-05 in MDD and AXS-07 in migraine, are on track for 4Q 2020. The company's cash at March 31, 2020 is expected to fund operations for at least two years.

Axsome Therapeutics reported a net loss of $24.8 million for Q4 2019, with increased R&D and G&A expenses due to ongoing clinical trials and commercial function build-out. The company's cash position significantly improved, ending the year with $220.0 million.